Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information
Captisol® is a modified cyclodextrin used for oral, ophthalmic, subcutaneous, and parenteral administration. By significantly improving the solubility, stability, bioavailability, and dosing of insoluble ingredients, we are the ideal product formulation for development, study, regulation, and manufacturing. Captisol® is not limited to pharma-related products and can be used in various supplements, personal care, and food and beverage products around the world.
The scientists at Ligand Pharmaceuticals are experts at working with Captisol®, have developed products in-house and aided clients in developing many successful formulations. Our expertise in navigating chemistry, manufacturing, and controls (CMC), regulatory, and clinical issues is unparalleled in the industry.
We offer unprecedented service to our partners due to our knowledge and competency in developing formulations with cyclodextrins and aided our partners in their development to have these products approved.
